Sheba’s Breakthrough Radiation Therapy for Pancreatic Cancer Pain: A Game-Changer in Oncology
This study introduces an innovative single-dose radiation therapy for pancreatic cancer pain relief, led by Dr. Yaakov Lawrence, Head of the Radiation Institute at Sheba’s Jusidman Cancer Center .
Pancreatic cancer poses a severe challenge due to its proximity to the celiac plexus, a nerve cluster responsible for intense pain. Traditional management approaches have included opioids and invasive procedures like celiac plexus blocks. However, Sheba’s study presents a groundbreaking alternative. The research, supported by Gateway for Cancer Research and the Israeli Cancer Association, focuses on delivering high-dose radiation directly to the celiac plexus, rather than the tumor itself.
Initially tested in a smaller-scale study at Sheba, the method showed promising results, leading to a larger international clinical trial involving eight hospitals across the United States, Canada, Poland, Portugal, and Israel. In Israel, Sheba, Assuta Ramat Hahayal, and Ichilov Hospital participated in the study.
Results from the trial, which included 125 patients, have been promising. 53% of participants reported significant pain reduction and improved quality of life. The treatment’s side effects were minimal, primarily consisting of fatigue and mild nausea.
The study’s success has been recognized with its inclusion in the National Comprehensive Cancer Network (NCCN) guidelines, reflecting its potential to impact global oncology practices. This endorsement signifies a major advancement in cancer pain management and highlights Sheba’s role as a leader in innovative cancer care.
Dr. Lawrence noted the importance of this achievement, stating, “Our inclusion in the NCCN guidelines represents a major milestone for oncology and underscores Sheba’s commitment to advancing treatment standards. This study not only demonstrates our capability in pioneering research but also contributes to improving global cancer care protocols.”
The collaborative efforts of Sheba’s team, including Prof.Talia Golan, Dr. Maoz Ben-Ayion, and Prof. Zvi Symon, were instrumental in achieving these results. Their work underscores Sheba’s dedication to excellence in research and its influence on international cancer treatment standards.
More Posts
Sheba’s Prof. Amitai Ziv Awarded by IMSH for Medical Simulation Excellence
Prof. Amitai Ziv, Founder of MSR-Azrieli Medical Simulation Center and Director of the Rehabilitation Hospital at Sheba Medical Center, has received...
Sheba’s Physicians Sweep Forbes Israel’s 2025 “Best Doctors” List
Forbes Israel has named an exceptional number of Sheba Medical Center’s physicians on its 2025 “Best Doctors” list. Earlier this year, Sheba was ranked by Newsweek as one of the World’s Top 10 Hospitals. This recognition and alignment between institutional and individual excellence signals to the global medical community that Sheba concentrates many of Israel’s most trusted clinical leaders under one roof.
Twinning and Training: Scalable Solutions for Global Eye Cancer Equity
Sheba Global Ophthalmology (SGO) demonstrates how sustainable twinning and hands-on training create self-reliant ocular oncology capacity in low- and middle-income countries (LMICs), far surpassing the limitations of short-term outreach.
